GlassScriptPhysician profile
Aruna S Agni
NPI 1801917786
$23,195.09
in general payments reported to CMS, 2019-2025
18 companies · $4,688 in 2025
The $4,688 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,100 · 2020: $1,961 · 2021: $2,215 · 2022: $3,149 · 2023: $3,754 · 2024: $4,328 · 2025: $4,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,483.50 |
| Education | $287.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,476.59 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $3,636.66 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,984.45 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $2,598.26 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $2,128.50 | 2019-2022 | |
| Alkermes, INC. | $1,794.89 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $1,629.93 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $1,217.00 | 2019-2025 | Fanapt |
| Lundbeck LLC | $1,046.29 | 2019-2025 | Rexulti, Abilify Asimtufii, Brintellix |
| E.R. Squibb & Sons, L.L.C. | $518.03 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $491.04 | 2021-2024 | Qelbree |
| Ironshore Pharmaceuticals INC. | $239.96 | 2019-2020 | |
| Neos Therapeutics, LP | $196.99 | 2019-2020 | |
| Vertical Pharmaceuticals, LLC | $156.17 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.00 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Validus Pharmaceuticals LLC | $24.25 | 2025 | Equetro |
| Janssen Pharmaceuticals, INC | $15.57 | 2019 | |
| Noven Therapeutics, LLC | $15.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aruna Agni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.